Albany, NY -- (SBWire) -- 06/11/2018 --Prostate-specific antigen (PSA) is a protein produced by the prostate cells. It is normally present in small quantities in the semen ejaculate of men with healthy prostates. However, elevated levels are observed in cases of prostate cancer or other prostate related diseases such as prostatitis or benign prostatic hyperplasia. PSA liquefies the semen in the seminal coagulum and allows sperm to swim freely. It is also believed to dissolve the cervical mucus, allowing the entry of sperm into the uterus. PSA tests involve measuring of the PSA amount in the blood sample of patients.

View Report: https://www.transparencymarketresearch.com/psa-testing-market.html

The global PSA testing market is categorized on the basis of the following clinical tests:

Prostate-specific antigen values
Free prostate-specific antigen assays
Complexed prostate-specific antigen assays
Prostate-specific antigen reverse transcription-polymerase chain reaction assays

Currently, North America dominates the global PSA testing market and is followed by Europe due to prostate cancer being most common type of cancer in men in these regions. Emerging economies of Asia-Pacific, Latin America, Middle East and Africa are also expected to undergo rapid market growth due to rising incidences of prostate related disorders.

Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2037

Major factors driving the growth of global PSA testing market include rising acceptance of serum-based marker testing for diagnosis of prostate cancer and its evaluation with other emerging cancer-specific markers to enhance the sensitivity of the test. However risk of over-diagnosis and overtreatment due to PSA screening may pose a challenge to the growth of this market.

Some of the key players contributing to the PSA testing market include Abbott Laboratories, Inc., AstraZeneca PLC, Bayer AG, Beckman Coulter, Inc., Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Company, Endocare, Inc., GE Healthcare, GlaxoSmithKline PLC, Medtronic, Inc., Merck & Company, Inc., Sanofi-aventis SA and Urologix, Inc.
Enquiry for Discount on this Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=2037

About Transparency Market Research
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR's syndicated reports strive to provide clients to serve their overall research requirement.

Contact Us
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com